Brokers Offer Predictions for Immunovant FY2026 Earnings

Immunovant, Inc. (NASDAQ:IMVT) – Equities research analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for shares of Immunovant in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst L. Chen expects that the company will post earnings per share of ($2.92) for the year. The consensus estimate for Immunovant’s current full-year earnings is ($2.75) per share.

Immunovant (NASDAQ:IMVT) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). During the same period last year, the firm earned ($0.45) EPS.

A number of other analysts have also issued reports on the stock. Bank of America decreased their target price on shares of Immunovant from $48.00 to $45.00 and set a “buy” rating on the stock in a research report on Wednesday, January 15th. HC Wainwright restated a “buy” rating and set a $51.00 target price on shares of Immunovant in a research report on Friday, November 8th. Wolfe Research lowered shares of Immunovant from an “outperform” rating to a “peer perform” rating in a research report on Friday, January 3rd. Oppenheimer raised their target price on shares of Immunovant from $47.00 to $53.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 9th. Finally, Raymond James restated an “outperform” rating and set a $36.00 target price on shares of Immunovant in a research report on Thursday, October 10th. One research analyst has rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $47.00.

Immunovant Stock Performance

Shares of NASDAQ IMVT opened at $23.05 on Thursday. Immunovant has a 1 year low of $22.41 and a 1 year high of $39.55. The firm’s 50 day moving average price is $25.93 and its 200 day moving average price is $28.39. The firm has a market cap of $3.38 billion, a P/E ratio of -10.38 and a beta of 0.66.

Insider Buying and Selling at Immunovant

In other news, CFO Eva Renee Barnett sold 4,174 shares of the firm’s stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $25.45, for a total value of $106,228.30. Following the transaction, the chief financial officer now owns 331,169 shares of the company’s stock, valued at approximately $8,428,251.05. This trade represents a 1.24 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Sciences Ltd. Roivant bought 16,845,010 shares of the business’s stock in a transaction dated Monday, January 13th. The stock was acquired at an average cost of $20.00 per share, for a total transaction of $336,900,200.00. Following the purchase, the director now owns 96,650,341 shares in the company, valued at approximately $1,933,006,820. This trade represents a 21.11 % increase in their position. The disclosure for this purchase can be found here. Insiders have sold a total of 72,892 shares of company stock worth $1,811,857 in the last quarter. 5.90% of the stock is owned by insiders.

Hedge Funds Weigh In On Immunovant

A number of hedge funds have recently made changes to their positions in the business. abrdn plc increased its stake in Immunovant by 11.1% during the 4th quarter. abrdn plc now owns 532,110 shares of the company’s stock worth $13,180,000 after buying an additional 53,353 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in Immunovant by 10.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 31,124 shares of the company’s stock worth $771,000 after buying an additional 2,973 shares during the period. KBC Group NV increased its stake in Immunovant by 60.1% during the 4th quarter. KBC Group NV now owns 3,099 shares of the company’s stock worth $77,000 after buying an additional 1,163 shares during the period. Principal Financial Group Inc. increased its stake in Immunovant by 69.9% during the 3rd quarter. Principal Financial Group Inc. now owns 951,124 shares of the company’s stock worth $27,117,000 after buying an additional 391,436 shares during the period. Finally, Tyro Capital Management LLC increased its stake in Immunovant by 0.6% during the 3rd quarter. Tyro Capital Management LLC now owns 252,149 shares of the company’s stock worth $7,189,000 after buying an additional 1,529 shares during the period. Hedge funds and other institutional investors own 47.08% of the company’s stock.

Immunovant Company Profile

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.